INSM logo

INSMED INC

INSMNASDAQ
🏆 #515 by market capEarnings Oct 29 · PreUS Equity
$97.17▲ $2.17 (+2.28%)
Market closed · at close
🔔
Track INSM
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 2.3%
7d▲ 2.2%
14d▼ 2.1%
30d▼ 15.9%
ytd▼ 44.2%
1y▼ 41.7%
🏦Market Cap
$21.22B
Mid Cap
📈Revenue Growth (YoY)
185.8%
High Growth
📊Gross Margin
83.5%
High
💵FCF Margin
—
⚖️P/S Ratio
18.6x
Expensive
Otter Score
52
Fair

Trading Snapshot

Day Range
$93.92 – $97.91
52-Week Range
$90.39 – $212.75
Volume (shares)
496,209
Avg Volume (shares)
—
Shares Outstanding
218.4M
Next Earnings
2026-10-29

Fundamentals Snapshot

Annual Revenue
$606M
Last Q Revenue
$425M
P/E Ratio
—
P/S Ratio
18.6x
EPS (TTM)
$-4.10
Dividend Yield
—
Dilution (1yr)
+19.3%
INSM logo

INSMED INC

INSM
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$606M▲ +66.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
79.4%▲ +3.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$1.2B▲ +34.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$968M▲ +37.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
213.6M▲ +19.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$258M▲ +$501M YoY
StockOtter · stockotter.space

About INSMED INC

Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
52/100

Analyst Ratings

ⓘ
Consensus
Buy
31 analysts
Strong Buy9
Buy21
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.